In silico drug discovery made easy
We use Big Data and Artificial Intelligence to
accelerate your novel Drug Development through:
Our very easy to use SaaS platform provides a versatile set of applications to facilitate target identification and elucidate the mechanisms of action (MoA).
From in silico Drug Design to computational prediction of ADME and pharmacokinetics.
Elucidate the Mode of Action (MoA) of specific molecules and rationalize their off-target effects.
In silico screening of libraries, hit & lead expansion and drug repurposing.
Identify and characterize binding sites using Artificial Intelligence approaches.
CataloniaBio & HealthTech has chosen its first president and board of directors today, after the merger of the CataloniaBio association of companies and the HealthTech Cluster last December, at an extraordinary members’ assembly. The candidacy led by Jaume...
Mind the Byte is delighted to announce the appointment Oriol Segarra, CEO of the pharmaceutical company Uriach, as a new member of the board of directors. With his more than 20 years of business experience in global pharmaceutical companies, he is an...
We are happy to announce that this week Mind the Byte has successfully released a new version of the SaaS platform for computational drug design. This new release consists on new versions of our ligand-based softwares, both 2D (Cabrakan, Chaac and Kizin) and 3D...